Pharmacokinetics and pharmacological effect of lerisetron, a new 5-HT3 antagonist, in rats

Journal of Pharmaceutical Sciences

Volumn 91, Issue 1, 2002, Pages 41-52

  Jauregizar, Nerea ^a   Calvo, Rosario ^a   Suarez, Elena ^a   Quintana, Antonio ^a   Raczka, Ewa ^a   Lukas, John C ^b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b University of Washington   (United States)

Author keywords

5 HT3 receptor antagonist; Active metabolite; Antiemetic; NONMEM; Pharmacodynamic; Pharmacokinetic; Population; Von Bezold Jarisch reflex

Indexed keywords

CARBON 14; LERISETRON; SEROTONIN 3 AGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INHIBITION; FEMALE; LIQUID CHROMATOGRAPHY; MALE; METABOLITE; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PROTEIN BINDING; RADIOACTIVITY; RAT; SCINTILLATION COUNTING; VOMITING;

EID: 0036142961     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.1169     Document Type: Article

References (28)

1. 3 antagonists. Synthesis and pharmacological evaluation
2. 3 receptors
3. Physiology of chemotherapy-induced emesis and antiemetic therapy
4. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy
5. Selective inhibition of the Bezold-Jarisch effect of 5-HT in the rat by antagonists at the neuronal 5-HT receptor
6. Serotonin (5-HT) receptor antagonism of 4,5,6,7-tetrahydrobenzimidazole derivatives against 5-HT induced bradycardia in anesthetized rats
7. 3 receptor antagonist
8. Antiemetic effects of lerisetron in radiation-induced emesis in the dog
9. Pharmacokinetic/pharmacodynamic relationship of lerisetron in control and tumor bearing rats: A pre-clinical study
10. Lerisetron PK-PD in vivo: Experimental results and comparison with a pharmacokinetic (unbound concentration) pharmacodynamic theory
11. 3 antagonist, in patients with cancer
12. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development
13. The case for preclinical pharmacodynamics
14. Determination of free valproic acid concentrations using the Amicon Micropartition MPS-1 ultrafiltration system
15. Comparison of NONMEM and NPEM with POP3CM, a new hierarchial parametric empirical Bayes model, using levofloxacin data
16. Relevance of the application of pharmacokinetic-pharmacodynamic modeling concepts in drug development. The "wooden shoe" paradigm
17. Disposition of the selective α1A-adrenoceptor antagonist tamsulosin in humans: Comparison with data from interspecies scaling
18. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs and humans
19. Does α-acid glycoprotein act as a functional receptor for α1-adrenergic antagonists?
20. 3 antagonist
21. Pharmacology, toxicology and human pharmacokinetics of tropisetron
22. Single and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: Part 2
23. Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans
24. Uptake of basic drugs into rat lung franule fraction in vitro
25. 3 receptor antagonist properties of ICS 205-930, GR 38032F and zacoprid
26. General persepectives on the role of metabolites in pharmacokinetics and pharmacodynamics
27. 1-receptor agonists with differing lipophilicity in rats: Comparison of pharmacokinetic, haemodynamic and EEG effects
28. Pharmacokinetic-Pharmacodynamic modeling of the electro-encephalographic effects of benzodiasepines. Correlation with receptor binding and anticonvulsant activity